Lupin inches up on securing USFDA`s approval for Armlupeg6 mg/0.6 mL injection
Lupin is currently trading at Rs. 2089.10, up by 8.10 points or 0.39% from its previous closing of Rs. 2081.00 on the BSE.
The scrip opened at Rs. 2099.80 and has touched a high and low of Rs. 2106.00 and Rs. 2083.70 respectively. So far 5077 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2106.00 and Rs. 1984.00 respectively. The current market cap of the company is Rs. 95737.35 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin has secured United States Food and Drug Administration’s (USFDA) approval for its Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta (pegfilgrastim) 6 mg/0.6 mL injection. The product will be manufactured at the company’s Biotech facility in Pune, which was inspected by the USFDA prior to approval. Armlupeg is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
